Vincerx Pharma, Inc.
VINC
$0.05
-$0.005-9.09%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.97M | 13.58M | 12.24M | 11.86M | 12.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.92M | 29.06M | 28.17M | 29.99M | 34.68M |
| Operating Income | -24.92M | -29.06M | -28.17M | -29.99M | -34.68M |
| Income Before Tax | -22.65M | -30.07M | -27.03M | -28.19M | -37.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.65 | -30.07 | -27.03 | -28.19 | -37.94 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.65M | -30.07M | -27.03M | -28.19M | -37.94M |
| EBIT | -24.92M | -29.06M | -28.17M | -29.99M | -34.68M |
| EBITDA | -24.87M | -29.01M | -28.12M | -29.93M | -34.63M |
| EPS Basic | -11.17 | -21.23 | -22.29 | -25.74 | -35.39 |
| Normalized Basic EPS | -6.31 | -12.60 | -13.93 | -16.09 | -22.12 |
| EPS Diluted | -11.17 | -21.23 | -22.29 | -25.74 | -35.39 |
| Normalized Diluted EPS | -6.31 | -12.60 | -13.93 | -16.09 | -22.12 |
| Average Basic Shares Outstanding | 8.88M | 6.39M | 5.22M | 4.71M | 4.28M |
| Average Diluted Shares Outstanding | 8.88M | 6.39M | 5.22M | 4.71M | 4.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |